Login to Your Account

Clinic Roundup

Monday, February 6, 2012

• Exelixis Inc., of South San Francisco, reported preliminary data from a Phase Ib drug interaction trial of cabozantinib in renal cell carcinoma, showing a high rate of durable tumor response, with a low rate of primary refractoriness to drug therapy, and a long median progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription